Navigation Links
Study shows interruption of antiretroviral therapy increases risk of disease and death

Findings from one of the largest HIV/AIDS therapy studies conducted to date show that a specific strategy of interrupting antiretroviral therapy more than doubles the risk of AIDS or death from any cause. Researchers affiliated with the Mailman School of Public Health and Harlem Hospital Hospital led a large multi-center international study, known as Strategies for Management of Anti-Retroviral Therapies, or SMART, comparing two treatment strategies for people with human immunodeficiency virus (HIV). Findings from the study, published in the November 30 New England Journal of Medicine, demonstrate the value of continuous antiretroviral therapy.

As HIV/AIDS has evolved into a chronic disease without a cure, lifelong antiretroviral therapy has become the norm. Lifelong therapy, however, can be difficult to adhere to as well as expensive. For these reasons, there has been a concerted research effort to test treatment interruption strategies that may enhance patients' quality of life and limit adverse drug effects.

The strategies evaluated in the SMART Study compared the recommended continuous use of antiretroviral therapy (anti-HIV medicines) with use of antiretroviral therapy in an episodic (interrupted) manner. The study found that the use of episodic antiretroviral therapy was inferior to continuous therapy as episodic therapy significantly increased the risk of opportunistic diseases or death from any cause. Further, episodic antiretroviral therapy did not reduce the risk of serious complications, including those related to the heart, kidneys, and liver.

Antiretroviral therapy in people with HIV is associated with remarkable benefits including longer survival and less illness. However, life-long treatment is difficult and can be associated with both short- and long-term risks, such as major metabolic and cardiovascular complications and built-up resistance to treatment. According to Wafaa El-Sadr, MD, MPH, co-chair of the SMART Study and p
'"/>

Source:Columbia University's Mailman School of Public Health


Page: 1 2 3

Related biology news :

1. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
2. Emory Study Tests Bone Marrow Stem Cells to Improve Circulation in Legs
3. UCLA Study Shows One-Third of Drug Ads in Medical Journals Do Not Contain References Supporting Medical Claims
4. Study Demonstrates Gene Expression Microarrays are Comparable and Reproducible
5. Study Links Ebola Outbreaks To Animal Carcasses
6. Breakthrough Microarray-based Technology for the Study of Cancer
7. NYU Study Reveals How Brains Immune System Fights Viral Encephalitis
8. Study finds more than one-third of human genome regulated by RNA
9. Leukemia Drug Breakthrough Study In New England Journal Of Medicine
10. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
11. New Study from Affymetrix Laboratories Points to Changing View of How Genome Works

Post Your Comments:
(Date:11/5/2009)...e University have developed synthetic molecules ca...IV and HIV-infected cells, as well as to prostate ...the Journal of the American Chemical Society , co... diseases. , The molecules called "antibody-re...body-recruiting molecule targeting prostate cancer...
(Date:11/4/2009)...are reluctant to officially endorse green tea as a...row about its protective effects, including result...esearch , a journal of the American Association fo...n oral cancer. , Vassiliki Papadimitrakopoulo, ...horacic/Head and Neck Medical Oncology at the Univ...
(Date:11/4/2009)...ies of Long Beach and Riverside are responsible fo...d asthma, and the true impact of air pollution and...erestimated, according to researchers at the Unive..., which appears in an online edition of the Ameri... percent of all childhood asthma cases in Long Bea...
Breaking Biology News(10 mins):New synthetic molecules trigger immune response to HIV and prostate cancer 2Does green tea prevent cancer? Evidence continues to brew, but questions remain 2USC study finds big air pollution impacts on local communities 2Sleep Deprivation Might Lead to Alzheimers 58288 1Sleep Deprivation Might Lead to Alzheimers 58288 2Vision for a Nation 3A Universal Access to Eyeglasses for the People of Rwanda 58283 1Vision for a Nation 3A Universal Access to Eyeglasses for the People of Rwanda 58283 2Mayo Clinic Offers Perspective on Health Care Reform in New England Journal of Medicine 58278 1Mayo Clinic Offers Perspective on Health Care Reform in New England Journal of Medicine 58278 2
...Calif., March 12 (OTC Bulletin Board: CICI) Commu..."Company"), a leading supplier of electronic signa...the financial industry* and the recognized leader*...day its financial results for the fourth quarter a...venues for the three months ended December 31, 200...
...Researchers at the University of Florida have intr... ,Delicious, ripens early, produces high yields, a...exceptional taste and texture with an edible skin,... and the potential for wine production. The name ,...ineyard visitors who sampled the fruit., According...
...f. - The most abundant material on Earth exhibits ... extreme conditions. , Lawrence Livermore Nationa...hot dense environments, plays an unexpected role i...st is a compound that speeds chemical reactions wi...mon catalysts. But water rarely, if ever, acts as ...
Other Biology News:Communication Intelligence Corporation Reports Fourth Quarter and Fiscal 2008 Results 2Communication Intelligence Corporation Reports Fourth Quarter and Fiscal 2008 Results 3Communication Intelligence Corporation Reports Fourth Quarter and Fiscal 2008 Results 4Communication Intelligence Corporation Reports Fourth Quarter and Fiscal 2008 Results 5Communication Intelligence Corporation Reports Fourth Quarter and Fiscal 2008 Results 6Water acts as catalyst in explosives 2
(Date:11/6/2009)...wire-FirstCall/ -- BioSpecifics Technologies Corp....eloping first-in-class collagenase-based products,...rd quarter ended September 30, 2009. ,, "We we..., the FDA,s Arthritis Advisory Committee unanimous... XIAFLEX(TM) for the treatment of Dupuytren,s dise...
(Date:11/6/2009)...ire/ -- Myriant Technologies LLC ("Myriant"), a pr...f renewable bio-chemicals, Uhde Corporation of Am...mbH, one of the world,s leading engineering contra...the engineering, procurement & construction (E...ed on renewable feedstocks. The execution of this...
(Date:11/6/2009)...ewswire-FirstCall/ -- ,, 3Q09 Corporate High... E.U. Marketing Authorization to Astellas Pharma E...al readiness activities Expanded management team ...nd Director, Commercial Operations Appointed Brad...mittee chairman , Upcoming 2009 Milestones:...
(Date:11/6/2009)...rstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDA...unced updated results from a Phase II study of int...astatic to the lung in a poster presentation at th...eeting held in Miami Beach, Florida, from November...Phase II Study of Intravenous REOLYSIN (Wild-type ...
Breaking Biology Technology:Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 2Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 3Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 4Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 5Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 6Myriant Technologies LLC, Uhde Corporation of America and Uhde GmbH Announce Alliance for Engineering, Procurement & Construction of World Scale Renewable Succinic Acid Plants 2Myriant Technologies LLC, Uhde Corporation of America and Uhde GmbH Announce Alliance for Engineering, Procurement & Construction of World Scale Renewable Succinic Acid Plants 3NeurogesX Reports Third Quarter 2009 Results 2NeurogesX Reports Third Quarter 2009 Results 3NeurogesX Reports Third Quarter 2009 Results 4NeurogesX Reports Third Quarter 2009 Results 5NeurogesX Reports Third Quarter 2009 Results 6NeurogesX Reports Third Quarter 2009 Results 7NeurogesX Reports Third Quarter 2009 Results 8NeurogesX Reports Third Quarter 2009 Results 9NeurogesX Reports Third Quarter 2009 Results 10Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 3
...st, Inc.,(NYSE: BMR ) today announced the signing...are feet at the Pacific Research Center, BioMed,s ...yStar Technologies, Inc.,(Nasdaq: DSTI ) will joi...the Pacific Research Center in the East Bay of San...ar is engaged in the development, manufacturing an...
...isnt always easy. However, shaking the bottle befo...to flow more freely because it becomes more fluid ... a liquid such as water does not become a gel when...e March 14 issue of the journal Physical Review Le...n oil are confined to a nanometer-sized space, the...
...rated,(Nasdaq: GPRO ) announced today that the Co...l Health Care Conference on May 6 at approximately...duled to be webcast live,and may be accessed throu...website at http://www.gen-probe.com . The webcast...., About Gen-Probe, Gen-Probe Incorporated is a ...
Other Biology Technology:BioMed Realty Trust Announces 140,000 Square Foot Lease With DayStar Technologies at Pacific Research Center 2BioMed Realty Trust Announces 140,000 Square Foot Lease With DayStar Technologies at Pacific Research Center 3Atomic force microscopy reveals liquids adjust viscosity when confined, shaken 2Atomic force microscopy reveals liquids adjust viscosity when confined, shaken 3Gen-Probe to Webcast Presentation at Deutsche Bank 33rd Annual Health Care Conference 2
...g system from Molecular Devices provides precise d...nt. The system handles a variety of plate formats ...-welland is the first to handle 1536-well micropla...ense from four different channels to accommodate u...
...you to identify over 150 peptide modifications sim...rms, protein subsets, and suppress false positives...ons and relationships easily. The software is idea...expression analysis for discovery research. The Pa...
Rabbit Anti-Human Rad51 Polyclonal Antibody, Unconjugated from Abcam
Rabbit Anti-Esa1 Polyclonal Antibody, Unconjugated from Abcam
Biology Products: